Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prognosis of COPD depends on severity of exacerbation history: A population-based analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Spousal bereavement after fibrotic interstitial lung disease: A qualitative study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Differentiation of adult severe asthma from difficult-to-treat asthma - Outcomes of a systematic assessment protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Self-reported intake of fruit and vegetables and risk of chronic obstructive pulmonary disease: A nation-wide twin study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Validation of ATS clinical practice guideline cut-points for FeNO in asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Uafklaret dyspnø.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hjertesygdomme

    Research output: Chapter in Book/Report/Conference proceedingBook chapterResearchpeer-review

  3. Exercise cardiovascular magnetic resonance imaging allows differentiation of low-risk pulmonary arterial hypertension

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Microfibrillar-associated protein 4 (MFAP4) is a matricellular glycoprotein that co-localises with elastic fibres and is highly expressed in the lungs. The aim of this study was to test the hypothesis that plasma MFAP4 (pMFAP4) reflects clinical outcomes in chronic obstructive pulmonary disease (COPD).

METHODS: pMFAP4 was measured by an AlphaLISA immunoassay in stable COPD (n = 69) at baseline and at follow-up until 24 months after inclusion and in acute exacerbations of COPD (AECOPD) (n = 14) at baseline and until 6 months after inclusion.

RESULTS: The majority of patients (89%) were in GOLD II and III. Multiple linear regressions showed positive associations between pMFAP4 and the Global initiative for Obstructive Lung Disease (GOLD) grade (p = 0.01), modified Medical Research Council score (p < 0.0001) and BODE index (p = 0.04). Negative associations were found with 6-min walking distance (p = 0.04) and bronchodilator-induced reversibility (p = 0.02). The pMFAP4 levels varied less than 25% between the baseline and a 3 month follow-up in 83% of the patients. The pMFAP4 levels appeared unaffected in the acute phase of severe AECOPD but rose to an increased stable level within one month after hospitalization.

CONCLUSION: Increased pMFAP4 was associated to the severity in COPD and has the potential to serve as a stable disease biomarker. This observation warrants confirmation in a larger longitudinal COPD population.

Original languageEnglish
JournalRespiratory medicine
Volume108
Issue number9
Pages (from-to)1336-44
Number of pages9
ISSN0954-6111
DOIs
Publication statusPublished - Sep 2014

ID: 44962666